Physician profile
Michael Mequio
NPI 1730328410
$2,533.61
in general payments reported to CMS, 2019-2025
16 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $49.50 · 2021: $155 · 2022: $242 · 2023: $550 · 2024: $315 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.34 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,108.16 | 2019-2025 | Clareon, Argos, Ngenuity |
| Allergan, INC. | $265.73 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $218.55 | 2022-2025 | Vyzulta, Infuse, Miebo |
| Abbvie INC. | $174.05 | 2023-2025 | |
| Oyster Point Pharma, INC. | $150.67 | 2023-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $143.23 | 2019-2022 | |
| Glaukos Corporation | $138.23 | 2020-2025 | Idosetr, Istent Infinite, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $85.40 | 2022-2023 | Cequa |
| Sight Sciences, INC. | $59.23 | 2022 | |
| Omeros Corporation | $47.74 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $47.71 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $21.39 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $20.22 | 2019 | |
| Genentech USA, INC. | $19.29 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.31 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mequio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.